{
    "nctId": "NCT02491892",
    "briefTitle": "A Study of Pertuzumab in Participants With Metastatic Breast Cancer",
    "officialTitle": "Open-Label, Phase II, Multicenter, Randomized Study of Efficacy and Safety for Two Different Doses of a Recombinant Humanized Antibody to HER2 (rhuMAb 2C4) Administered Every 3 Weeks to Patients With Metastatic Breast Cancer With Low Expression of HER2",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 79,
    "primaryOutcomeMeasure": "Percentage of Participants Achieving a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Females at least 18 years of age\n* Histologically-confirmed metastatic breast cancer with low HER2 expression and at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST)\n* Karnofsky performance status at least 80%\n* Disease progression on/after up to 2 different chemotherapy regimens, including an anthracycline-containing therapy\n* Left ventricular ejection fraction (LVEF) at least 50%\n* Adequate liver function\n\nExclusion Criteria:\n\n* Pleural effusions, ascites, or bone lesions as the only manifestation(s) of cancer\n* Pulmonary or central nervous system (CNS) metastases\n* Chemotherapy, radiotherapy, or immunotherapy within 4 weeks; or hormone therapy within 2 weeks of Day 1\n* Previous treatment with any drug that targets the HER2 receptor family\n* Previous treatment with corticosteroids as cancer therapy\n* History of significant cardiac disease\n* Major surgery or trauma within 4 weeks of Day 1\n* Pregnant or lactating women",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}